These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37818839)

  • 1. PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis.
    Zaza M; Rashed MH; Elrefaey H; Hassan MH; Abo-Salem OM; El-Sayed ESM
    Can J Physiol Pharmacol; 2024 Jan; 102(1):55-68. PubMed ID: 37818839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
    Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
    Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymoquinone Alterations of the Apoptotic Gene Expressions and Cell Cycle Arrest in Genetically Distinct Triple-Negative Breast Cancer Cells.
    Adinew GM; Messeha SS; Taka E; Badisa RB; Antonie LM; Soliman KFA
    Nutrients; 2022 May; 14(10):. PubMed ID: 35631261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
    Izetti P; Hautefeuille A; Abujamra AL; de Farias CB; Giacomazzi J; Alemar B; Lenz G; Roesler R; Schwartsmann G; Osvaldt AB; Hainaut P; Ashton-Prolla P
    Invest New Drugs; 2014 Oct; 32(5):783-94. PubMed ID: 24838627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines.
    Deben C; Lardon F; Wouters A; Op de Beeck K; Van den Bossche J; Jacobs J; Van Der Steen N; Peeters M; Rolfo C; Deschoolmeester V; Pauwels P
    Cancer Lett; 2016 Jun; 375(2):313-322. PubMed ID: 26975633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax.
    Wang T; Lee K; Rehman A; Daoud SS
    Biochem Biophys Res Commun; 2007 Jan; 352(1):203-12. PubMed ID: 17113036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dillenia suffruticosa dichloromethane root extract induced apoptosis towards MDA-MB-231 triple-negative breast cancer cells.
    Foo JB; Saiful Yazan L; Tor YS; Wibowo A; Ismail N; Armania N; Cheah YK; Abdullah R
    J Ethnopharmacol; 2016 Jul; 187():195-204. PubMed ID: 27131434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effect of chrysin and radiotherapy against triple-negative breast cancer (TNBC) cell lines.
    Jafari S; Dabiri S; Mehdizadeh Aghdam E; Fathi E; Saeedi N; Montazersaheb S; Farahzadi R
    Clin Transl Oncol; 2023 Aug; 25(8):2559-2568. PubMed ID: 36964888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.
    Synnott NC; Bauer MR; Madden S; Murray A; Klinger R; O'Donovan N; O'Connor D; Gallagher WM; Crown J; Fersht AR; Duffy MJ
    Cancer Lett; 2018 Feb; 414():99-106. PubMed ID: 29069577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.
    Simon M; Mesmar F; Helguero L; Williams C
    PLoS One; 2017; 12(2):e0172832. PubMed ID: 28235006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of AKT/PI3K Pathway in Sanguinarine's Induced Apoptosis and Cell Cycle Arrest in Triple-negative Breast Cancer Cells.
    Messeha SS; Noel S; Zarmouh NO; Womble T; Latinwo LM; Soliman KFA
    Cancer Genomics Proteomics; 2023; 20(4):323-342. PubMed ID: 37400144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene Expression Alterations Associated with Oleuropein-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Triple-Negative Breast Cancer Cells.
    Messeha SS; Zarmouh NO; Asiri A; Soliman KFA
    Nutrients; 2020 Dec; 12(12):. PubMed ID: 33297339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant P53 modulation by cryptolepine through cell cycle arrest and apoptosis in triple negative breast cancer.
    Qayoom H; Mir MA
    Biomed Pharmacother; 2024 Oct; 179():117351. PubMed ID: 39216450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRIMA-1 induces p53-mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation.
    Furukawa H; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
    Cancer Sci; 2018 Feb; 109(2):412-421. PubMed ID: 29168598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells.
    O'Grady S; Crown J; Duffy MJ
    Med Oncol; 2022 Jul; 39(10):142. PubMed ID: 35834073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chk1 inhibition-induced BRCAness synergizes with olaparib in p53-deficient cancer cells.
    Zhao Y; Zhou K; Xia X; Guo Y; Tao L
    Cell Cycle; 2023 Jan; 22(2):200-212. PubMed ID: 35959961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells.
    Messina RL; Sanfilippo M; Vella V; Pandini G; Vigneri P; Nicolosi ML; Gianì F; Vigneri R; Frasca F
    Int J Cancer; 2012 May; 130(10):2259-70. PubMed ID: 21647879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.